PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Agarikon pill (AGKP) improved lung function and pathological changes in rat models [PMID:39262658]
Chloroformic extracts promoted cancer cell apoptosis in HepG2 and LO2 cell lines in vitro [PMID:34102992]
Medicinal mushroom preparations (AGARIKON.1 and AGARIKON PLUS) showed antiproliferative and pro-apoptotic effects on HCT-116 and SW620 tumor cell lines in vitro [PMID:33126765]
Chlorinated coumarins isolated from the mushroom demonstrated antimicrobial activity against the M. tuberculosis complex [PMID:24087924]
Lanostane triterpenoids exhibited moderate inhibitory activity (IC50 7.0-27.1 μM) [PMID:29417466]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 40370689 (2024) — Neuroprotective Mushrooms. · NeuroImmune pharmacology and therapeutics
- 2.PMID: 30834150 (2019) — Antimicrobial properties of Fomitopsis officinalis in the light of its bioactive metabolites: a review. · Mycology
- 3.PMID: 32271491 (2020) — Fomitopsis officinalis: a Species of Arboreal Mushroom with Promising Biological and Medicinal Properties. · Chemistry & biodiversity
- 4.PMID: 30143116 (2018) — Structure characterization of the mannofucogalactan isolated from fruit bodies of Quinine conk Fomitopsis officinalis. · Carbohydrate polymers
- 5.PMID: 34102992 (2022) — Anti-oxidant and Anticancerous Effect of Fomitopsis officinalis (Vill. ex Fr. Bond. et Sing) Mushroom on Hepatocellular Carcinoma Cells In Vitro through NF-kB Pathway.